[go: up one dir, main page]

WO2008091408A3 - Rénalase circulante et procédés d'augmentation de celle-ci - Google Patents

Rénalase circulante et procédés d'augmentation de celle-ci Download PDF

Info

Publication number
WO2008091408A3
WO2008091408A3 PCT/US2007/079411 US2007079411W WO2008091408A3 WO 2008091408 A3 WO2008091408 A3 WO 2008091408A3 US 2007079411 W US2007079411 W US 2007079411W WO 2008091408 A3 WO2008091408 A3 WO 2008091408A3
Authority
WO
WIPO (PCT)
Prior art keywords
renalase
circulating
protein
methods
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/079411
Other languages
English (en)
Other versions
WO2008091408A2 (fr
Inventor
Gary V Desir
Jianchao Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of WO2008091408A2 publication Critical patent/WO2008091408A2/fr
Publication of WO2008091408A3 publication Critical patent/WO2008091408A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0022—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des procédés d'utilisation de la rénalase en tant que protéine thérapeutique sous sa forme mûre transformée. Il est possible d'administrer de la rénalase sous sa forme circulante à des individus présentant des niveaux bas de rénalase, afin de leur fournir une réserve adéquate de protéines. La forme circulante de la protéine rénalase peut être administrée à des individus ayant besoin d'une réduction immédiate des niveaux de catécholamine. L'invention concerne en outre un procédé de traitement d'un patient qui présente une maladie caractérisée par un niveau accru de catécholamines circulantes. Ledit procédé consiste en l'administration d'une bouffée de catécholamine audit patient en une quantité efficace, afin d'augmenter l'activité de la rénalase circulante.
PCT/US2007/079411 2006-09-25 2007-09-25 Rénalase circulante et procédés d'augmentation de celle-ci Ceased WO2008091408A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84676206P 2006-09-25 2006-09-25
US60/846,762 2006-09-25

Publications (2)

Publication Number Publication Date
WO2008091408A2 WO2008091408A2 (fr) 2008-07-31
WO2008091408A3 true WO2008091408A3 (fr) 2008-10-16

Family

ID=39645028

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/079411 Ceased WO2008091408A2 (fr) 2006-09-25 2007-09-25 Rénalase circulante et procédés d'augmentation de celle-ci

Country Status (1)

Country Link
WO (1) WO2008091408A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015175884A2 (fr) 2014-05-16 2015-11-19 Yale University Compositions et procédés de traitement et de prévention de la pancréatite, d'une lésion rénale et du cancer
EP3598980A3 (fr) * 2014-06-26 2020-04-15 Yale University Compositions et procédés permettant de réguler la rénalase dans le traitement de maladies et de troubles

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005089505A2 (fr) * 2004-03-19 2005-09-29 Yale University Detection, isolement et utilisations de la renalase (monoamine oxydase de type c)
WO2007059357A1 (fr) * 2005-11-21 2007-05-24 Yale University Procedes de regulation de la renalase (monoamine oxydase c)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005089505A2 (fr) * 2004-03-19 2005-09-29 Yale University Detection, isolement et utilisations de la renalase (monoamine oxydase de type c)
US20070275083A1 (en) * 2004-03-19 2007-11-29 Jianchao Xu Detection, Isolation and Uses Of Renalase (Monoamine Oxidase C)
WO2007059357A1 (fr) * 2005-11-21 2007-05-24 Yale University Procedes de regulation de la renalase (monoamine oxydase c)
US20070248585A1 (en) * 2005-11-21 2007-10-25 Gary Desir Methods of regulating renalase (Monoamime Oxidase C)

Also Published As

Publication number Publication date
WO2008091408A2 (fr) 2008-07-31

Similar Documents

Publication Publication Date Title
WO2010151755A3 (fr) Traitement de maladies inflammatoires à l'aide du microarn mir-124
WO2011014255A8 (fr) Traitement de la maladie de crohn au moyen de laquinimod
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
NZ778131A (en) Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2009050506A3 (fr) Combinaison 059
ME02450B (fr) Traitements antitumoraux perfectionnés
WO2009073544A3 (fr) Procédés de traitement d'un trouble par régulation de gprc6a
MX2010012860A (es) Metodos para tratar cancer del sistema nervioso central.
WO2007105203A3 (fr) Procede et composition pour la protection du tissu neuronal de degats induits par des niveaux eleves de glutamate
WO2007095056A3 (fr) Administration intraventriculaire lente
WO2008147483A8 (fr) Composés neurogéniques
WO2008012796A3 (fr) Compositions pharmaceutiques comprenant ccl2 et leur utilisation dans le traitement d'une inflammation
WO2006055352A3 (fr) Methodes de traitement du cancer avec des formulations de composes de platine a base lipipique administrees par voie intraperitoneale
WO2008073466A3 (fr) Alpha b-cristalline en tant que traitement de l'inflammation
WO2008091408A3 (fr) Rénalase circulante et procédés d'augmentation de celle-ci
GB0405381D0 (en) A method and means for treating heart failure
WO2011022633A3 (fr) Procédé de traitement du cancer
MX2009004646A (es) Agente que comprende g-csf para la prevencion y el tratamiento de la neuropatia periferica diabetica.
MX366496B (es) Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso.
WO2009105756A3 (fr) Protection de rétine neuronale par réduction du métabolisme des bâtonnets
TW200738255A (en) Methods of regulating renalase (Monoamine Oxidase C)
HK1209041A1 (en) A method of weight reduction
WO2007133749A3 (fr) Méthodes et compositions pour traiter et prévenir une lésion d'un nerf périphérique
WO2008143014A1 (fr) Agent thérapeutique pour le cancer
MX2009006670A (es) Composicion farmaceutica que usa el aliskiren y el avosentan.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07872768

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07872768

Country of ref document: EP

Kind code of ref document: A2